These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 23934911)

  • 21. The unregulated commercialization of stem cell treatments: a global perspective.
    Sipp D
    Front Med; 2011 Dec; 5(4):348-55. PubMed ID: 21964637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FDA challenges stem-cell clinic.
    Cyranoski D
    Nature; 2010 Aug; 466(7309):909. PubMed ID: 20725009
    [No Abstract]   [Full Text] [Related]  

  • 23. Stem cell science: current ethical and policy issues.
    Mauron A; Jaconi ME
    Clin Pharmacol Ther; 2007 Sep; 82(3):330-3. PubMed ID: 17637783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.
    Coppens DGM; de Wilde S; Guchelaar HJ; De Bruin ML; Leufkens HGM; Meij P; Hoekman J
    Cytotherapy; 2018 Jun; 20(6):769-778. PubMed ID: 29730080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stem-cell-derived products: an FDA update.
    Moos M
    Trends Pharmacol Sci; 2008 Dec; 29(12):591-3. PubMed ID: 18937983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulatory and policy tools to address unproven stem cell interventions in Canada: the need for action.
    Caulfield T; Murdoch B
    BMC Med Ethics; 2019 Aug; 20(1):51. PubMed ID: 31383026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Need for Beneficence and Prudence in Clinical Innovation with Autologous Stem Cells.
    Lipworth W; Stewart C; Kerridge I
    Perspect Biol Med; 2018; 61(1):90-105. PubMed ID: 29805150
    [TBL] [Abstract][Full Text] [Related]  

  • 28. US stem cell clinics, patient safety, and the FDA.
    Turner L
    Trends Mol Med; 2015 May; 21(5):271-3. PubMed ID: 25945404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The limits of free speech.
    Nature; 2012 Dec; 492(7429):311. PubMed ID: 23281497
    [No Abstract]   [Full Text] [Related]  

  • 30. Market exclusivity for biologics.
    Wheadon DE
    N Engl J Med; 2010 Feb; 362(7):661; author reply 661-2. PubMed ID: 20164494
    [No Abstract]   [Full Text] [Related]  

  • 31. Direct-to-consumer marketing of stem cell interventions by Canadian businesses.
    Turner L
    Regen Med; 2018 Sep; 13(6):643-658. PubMed ID: 30255734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Next-generation stem cell therapy poised to enter EU market.
    Dolgin E
    Nat Biotechnol; 2015 Mar; 33(3):224-5. PubMed ID: 25748900
    [No Abstract]   [Full Text] [Related]  

  • 33. Stem cells. U.S. regulation of stem cells as medical products.
    Sipp D; Turner L
    Science; 2012 Dec; 338(6112):1296-7. PubMed ID: 23224541
    [No Abstract]   [Full Text] [Related]  

  • 34. The Food and Drug Administration, regenerative sciences, and the regulation of autologous stem cell therapies.
    von Tigerstrom B
    Food Drug Law J; 2011; 66(4):479-506, i. PubMed ID: 24505826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Australian regulation of autologous human cell and tissue products: implications for commercial stem cell clinics.
    Ghinea N; Munsie M; Rudge C; Stewart C
    Regen Med; 2020 Feb; 15(2):1361-1369. PubMed ID: 32228372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cannabidiol (CBD) in Dietary Supplements: Perspectives on Science, Safety, and Potential Regulatory Approaches.
    Walker LA; Koturbash I; Kingston R; ElSohly MA; Yates CR; Gurley BJ; Khan I
    J Diet Suppl; 2020; 17(5):493-502. PubMed ID: 32543246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Off-label or off-limits?
    Ratner M; Gura T
    Nat Biotechnol; 2008 Aug; 26(8):867-75. PubMed ID: 18688236
    [No Abstract]   [Full Text] [Related]  

  • 38. Ethical and Regulatory Challenges with Autologous Adult Stem Cells: A Comparative Review of International Regulations.
    Lysaght T; Kerridge IH; Sipp D; Porter G; Capps BJ
    J Bioeth Inq; 2017 Jun; 14(2):261-273. PubMed ID: 28247202
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vulnerabilities and the Use of Autologous Stem Cells for Medical Conditions in Australia.
    Hendl T
    Perspect Biol Med; 2018; 61(1):76-89. PubMed ID: 29805149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.